morpholine)acetate, ethyl 2-acetamido-2-(N-anilino)acetate, ethyl 2-acetamido-2-(N-(3-pyrazolylamino))acetate, ethyl 2-acetamido-2-(N-hydroxyamino)acetate, ethyl 2-acetamido-2-(N-(N-methylhydroxyamino))acetate, ethyl 2-acetamido-2-(N-(N,O-dimethylhydroxyamino))acetate, 2-acetamido-N-benzyl-2-aminoacetamide, 2-acetamido-N-benzyl-2-(methylamino)acetamide, 2-acetamido-N-benzyl-2-(ethylamino)acetamide, 2-acetamido-N-benzyl-2-(N-anilino)acetamide, 2-acetamido-N-benzyl-2(N-(3-pyrazolylamino))acetamide, 2-acetamido-N-benzyl-2-(N,N-dimethylamino)acetamide, 2-acetamido-N-benzyl-2-(N-hydroxyamino)acetamide, 2-acetamido-N-benzyl-2-(N-hydroxyamino)acetamide, 2-acetamido-N-benzyl-2-(N^2-phenylhydrazino)acetamide, 2-acetamido-N-benzyl-2-(N^2-benzyloxycarbonylhydrazino)acetamide, 2-acetamido-N-benzyl-2-phenoxyacetamide, 2-acetamido-N-benzyl-2-(methylmercapto)acetamide, 2-acetamido-N-benzyl-2-(ethylmercapto)acetamide, 2-acetamido-N-benzyl-2-(N-methoxyamino)acetamide, 2-acetamido-N-benzyl-2-(N-(N-methylhydroxyamino))acetamide, 2-acetamido-N-benzyl-2-(N-(N,O-dimethylhydroxyamino))acetamide, 2-acetamido-N-benzyl-2-(N-isoxazolidino)acetamide, 2-acetamido-N-benzyl-2-hydroxyacetamide, 2-acetamido-N-benzyl-2-(ethylmercapto)acetamide, 2,2-diacetamido-N-benzylacetamide, 2-acetamido-N-benzyl-2-trifluoracetamidoacetamide, 2-acetamido-N-benzyl-2-(N,N,N-trimethylammonium)acetamide tetrafluoroborate, 2-acetamido-N-benzyl-2-(ethylmercapto)acetamide-S-oxide, 2-acetamido-N-benzyl-2-(S-ethylmercapto) acetamide-S-oxide, 2-acetamido-N-benzyl-2-(ethanesulfonyl)acetamide, 2-acetamido-N-benzyl-2-(N,N,N-trimethylammonium)acetamide tetrafluoroborate, 2-acetamido-N-benzyl-2-(1-pyrrole)acetamide, 2-acetamido-N-benzyl-2-(1-imidazole)acetamide, 2-acetamido-N-benzyl-2-(1-pyrazole)acetamide, 2-acetamido-N-benzyl-2(1-(1,2,4-triazole))acetamide, 2-acetamido-N-benzyl-2(1-tetrazole))acetamide, α-acetamido-N-benzyl-2-pyridylacetamide, α-acetamido-N-benzyl-2-pyridyl acetamide N-oxide, α-acetamido-N-benzyl-2-(S-thiophenoxy)-acetamide, α-acetamido-N-benzyl-2-(tetrahydrofuran)acetamide, methyl α-acetamido-2-methyl-2-furanacetate, α-acetamido-2-methyl-2-furanacetic acid, α-acetamido-N-benzyl-2-methyl-2-furanacetamide, α-thioacetamido-N-benzyl-2-furanacetamide, α-thioacetamido-N-benzyl-2-furanthioacetamide, α-acetamido-N-(3-pyridinylmethyl)-2-furanacetamide, α-acetamido-N-(4-pyridinylmethyl)-2-furanacetamide, α-acetamido-N-(1-oxo-3-pyridinylmethyl) -2-furanacetamide, α-acetamido-N-(1-oxo-4-pyridinylmethyl)-2-furanacetamide, R(−)α-acetamido-N-(4-fluorobenzyl)-2-furanacetamide, R(−)α-acetamido-N-(4-trifluoromethylbenzyl)-2-furanacetamide, methyl [acetamido(benzylcarbamoyl)methyl]carbomate, phenyl [acetamido(benzylcarbamoyl)methyl]carbomate, 1-[acetamido(benzylcarbamoyl)methyl]-3-methylurea), 1-[acetamido(benzylcarbamoyl)methyl]-3-phenylurea), 1-[acetamido(benzylcarbamoyl)methyl]-3-benzenesulfonylurea), 1-[acetamido(benzylcarbamoyl) methyl]-3-methylthiourea), 1-[acetamido(benzylcarbamoyl) methyl]-3-phenylthiourea), N-[acetamido (benzylcarbamoyl)methyl]phthalamic acid), 2-acetamido-N-benzyl-2-(N-succinimidyl)acetamide), benzyl N-[acetamido(benzylcarbamoyl)methyl]malonamate, ethyl N-[acetamido(benzylcarbamoyl)methyl]glycinate, benzyl N-[acetamido(benzylcarbamoyl)methyl]glycinate, N-[acetamido(benzylcarbomoyl)methyl]glycine, 2-acetamide-N-benzyl-2-(1-pyrrole)acetamide, 2-acetamido-N-benzyl-2-(1-pyrazole)acetamide, 2-acetamido-N-benzyl-2-(1-imidazole)acetamide. 2-acetamido-N-benzyl-2-(1-(1,2,4-triazole))acetamide, 2-acetamido-N-benzyl-2-(1-tetrazole))acetamide, α-acetamido-N-benzyl-1-(dimethylsulfamoyl)imidazole-4-acetamide, α-acetamido-N-benzyl-4-imidazole acetamide, α-acetamido-N-benzyl-2-imidazole acetamide, α-acetamido-N-benzyl-5-(tetrazole)acetamide, α-acetamido-N-benzyl-3-(1,2,4-triazole)acetamide. α-acetamido-N-benzyl-2-(carboxamide oxime)acetamide, α-acetamido-N-benzyl-2-(carboxamide oxime-(O-acetate))-acetamide, α-acetamido-N-benzyl-3-(1,2,4-oxadiazole) acetamide, α-acetamido-N-benzyl-2-(thioamide) acetamide), 2-acetamido-N-benzyl-2-vinylacetamide, 2-acetamido-N-benzyl-2-epoxyacetamide, potassium 2-acetamido-N-benzylacetamide-2-sulfonate, 2-acetamido-4-pentenic acid-N-benzylamide, α-acetamido-N-benzyl-2-(2-oxazole)-acetamide, and α-acetamido-N-benzyl-2-(2-thiazole)-acetamide.

23. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from any one of claims **1–15** and **22** and a pharmaceutical carrier therefor.

24. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from claim **16** and a pharmaceutical carrier therefor.

25. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from claim **17** and a pharmaceutical carrier therefor.

26. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from claim **18** and a pharmaceutical carrier therefor.

27. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound of claim **19** and a pharmaceutical carrier therefor.

28. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound of claim **20** and a pharmaceutical carrier therefor.

29. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound of claim **21** and a pharmaceutical carrier therefor.

30. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound according to any one of claims **1–15** and **22**.

31. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim **16**.

32. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim **17**.

33. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim **18**.

34. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim **19**.

35. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim **20**.

36. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim **21**.

37. The compound according to any one of claims **1**, **10**, **12** or **14** wherein n is 1 and R is lower alkyl which is unsubstituted or substituted with an electron donating group or electron withdrawing group.

38. The compound according to any one of claims **1**, **10**, **12** or **14** wherein n is 1; R_1 is methyl and R is lower arylalkyl

which is unsubstituted or substituted with an electron withdrawing group or electron donating group.

39. A compound of the formula



(I)

or the pharmaceutically acceptable salts thereof wherein

R is aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, cycloalkyl or lower cycloalkyl lower alkyl, wherein R is unsubstituted or is substituted with at least one electron withdrawing group or an electron donating group;

R_1 is hydrogen or lower alkyl and R_1 is unsubstituted or substituted with at least one electron withdrawing group or at least one electron donating group;

A and Q are both O;

one of R_2 and R_3 is hydrogen and the other is lower alkyl which is substituted with an electron donating group or a electron withdrawing group and n is 1–4.

40. The compound according to claim **39** wherein one of R_2 and R_3 is hydrogen and the other is lower alkyl substituted with an electron donating group.

41. The compound according to claim **40** wherein one of R_2 and R_3 is alkyl substituted with an electron donating group wherein alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, amyl or hexyl.

42. The compound according to claim **41** wherein one of R_2 and R_3 is methyl substituted with an electron donating group.

43. The compound according to claim **42** wherein the electron donating group is lower alkoxy.

44. The compound according to claim **43** wherein lower alkoxy is methoxy.

45. The compound according to any one of claims **39–44** wherein n is 1.

46. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from any one of claim **37–42** and a pharmaceutical carrier therefor.

47. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of any one of claims **39–44**.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 5,654,301
DATED : August 5, 1997
INVENTOR(S) : Harold Kohn, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 34,
Line 59: "Ch $_3$ H)" should read -- C_3 H) --
Line 59: "8.62 Hz" should read -- 8.62 (d,J=7.7 --
Line 60: "H," should read -- Hz, --

Column 35,
Line 15: "form" should read -- formed --
Line 35: "8.89" should read -- 8.99 --

Column 37,
Line 53: "α" should read -- 2 --
Line 60: "or" should read -- of --

Column 38,
Line 65: "13_c" should read -- 13 $_C$ --

Column 40,
Line 25: "2.33" should read -- 2.23 --
Line 25: "425" should read -- 4.25 --
Line 67: "(M^{30}=1)" should read -- (M^+= 1) --

Column 41,
Line 25: "2-hydroxyamino" should read -- 2-(N-hydroxyamino) --

Column 42,
Line 55: "(M^+ + 100)" should read -- (M^+ + 1,100) --

Column 19,
Line 30: "intraperitoncally" should read -- intraperitoneally --

Column 27,
Line 45: "16 ° " should read -- 169 ° --

Column 28,
Line 56: "7.1.7" should read -- 7.17 --

Column 30,
Line 37: "63" should read -- 6.3 --
Line 64: "785" should read -- 735 --

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 5,654.301
DATED : August 5, 1997
INVENTOR(S) : Harold Kohn, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 31,
Line 21: "cbloroform" should read -- chloroform --
Line 49: "2.78" should read -- 2.75 --

Column 33,
Line 16: "(D,L" should read -- (D,L) --
Line 38: "94:4" should read -- 96:4 --
Lines 41 & 42: "80" should read -- 8.0 --
Line 48: "$C_{3'}$ "should read -- $C_{6'}$ --

Column 34,
Line 15: "130" should read --139 --
Line 41: "M + 1" should read -- M^+ + 1 --

Column 43,
Lines 21 & 49: "acetamido" should read -- acetamide --
Line 59: "1.84'" should read -- 1.84 --

Column 44,
Line 46, "n" should read -- a --
Line 46: "ethoxyacetamido" should read -- ethoxyacetamide --
Line 65: "acetamido" should read -- acetamide --

Column 45,
Line 18: after "spectrum" insert -- (FD) --
Line 39: "7.5" should read -- 7.52 --
Line 56: "73.3" should read -- 7.33 --

Column 46,
Line 25: "CH_3Cl_2," should read -- CH_2Cl_2 --

Column 49,
Lines 57-58: "O-methylhydroxyamino" should read -- O-dimethylhydroxyamino --

Column 50,
Line 40: "149" should read -- 14.9 --

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 5,654.301
DATED : August 5, 1997
INVENTOR(S) : Harold Kohn, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 51,
Line 24: "accetamido" should read -- acetamide --
Line 38: "Dicacetamido" should read -- Diacetamide --
Line 46: "and-was" should read -- and was --

Column 52,
Line 16: "166.3.9" should read -- 166.39 --

Column 54,
Line 16: "Time" should read -- The --

Column 55,
Line 7: "H" should read -- It --

Column 56,
Line 55: "C_1 " should read -- C_{12} --
Line 66: "while" should read -- white --
Line 66: "alter" should read -- after --

Column 58,
Line 30: "dr" should read -- dt --

Column 59,
Line 62: after "1.89" insert -- (s, --
Line 63: Delete -- (s, --

Column 60,
Line 4: "1" should read -- 91 --

Column 61,
Line 30: "(C_2), H" should read -- CH_2), --

Column 63,
Line 38: "add" should read -- acid --

Column 65,
Line 10: "8.62" should read -- 8.61 --
Line 21: "arthydride" should read -- anhydride --

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.